Insider
Resmed IncRMD

ResMed earnings per share rose in the first quarter of fiscal year 2027

ResMed reported GAAP earnings per share (EPS) of $2.92 for the first quarter of fiscal year 2027, up 23% from the prior year. Adjusted EPS was $2.91, up 14%.

Verified against 4 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
A medical monitor displaying vital signs with green waveforms on a dark screen
Photo by Jair Lázaro on Unsplash
$2.92
GAAP EPS
$422 million
Operating cash flow
$0.66
Quarterly dividend

Key points

  • The company generated $422 million in operating cash flow for the first quarter, with free cash flow of $374 million.
  • ResMed updated its presentation of restructuring and intangible asset amortization expenses this period.

Financial results and corporate events

The company generated $422 million in operating cash flow for the first quarter, with free cash flow of $374 million. It returned over $1 billion to shareholders through share repurchases and dividends.

The board of directors declared a quarterly dividend of $0.66 per share, payable on December 17, 2026. The company also completed the divestiture of MatrixCare, launched the AirTouch F40 CPAP mask, and appointed Carol Burt as lead director, effective November 15, 2026.

Michael J. Ryder, global general counsel, sold 400 shares on October 23, 2026, at a weighted average price of $255 per share under a 10b5-1 plan, a preset selling schedule executives set up in advance.

Revenue by quarter, $B

1.3Q2 '2532.5%1.3Q3 '2533%1.3Q4 '25*33.7%1.3Q1 '2633.4%1.4Q2 '2634.6%1.4Q3 '2634.9%1.5Q4 '26*30.7%1.4Q1 '2732%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.

Changes in financial reporting

ResMed updated its presentation of restructuring and intangible asset amortization expenses this period. Restructuring expenses are now classified as business transformation expenses allocated by function, rather than as a separate line item. These adjustments did not impact previously reported revenue or cash flow figures.

What to expect next

Shareholders should note the dividend payment date of December 17, 2026, and the start of Carol Burt's term as lead director on November 15, 2026.

Original sources

  1. 8-K filing, October 29, 2026October 29, 2026SHA-256 of our archived copy abadce05af24…
  2. 8-K EX-99.1 filing, October 29, 2026October 29, 2026SHA-256 of our archived copy f82bd6439b99…
  3. 144 filing, October 23, 2026October 23, 2026SHA-256 of our archived copy 7fc14d7cc712…
  4. 4 filing, October 26, 2026October 26, 2026SHA-256 of our archived copy c3e482d81100…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards